MeSH tree: N04.761.559.590.800.569
Researchers at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy have released updated consensus guidelines and an associated reproducibility study to standardize how pathologists ...
Feb 4, 2026
0
7
She has helped robots learn to get around indoors and pick up balls from the ground. And she has developed computer programs to monitor traffic at intersections.
Sep 29, 2025
0
15
Researchers at the University of Tsukuba have investigated the changes in the primary evaluation items in phase II clinical trials for glioblastoma, a type of brain tumor. Recently, the items have become more diverse, with ...
Mar 21, 2025
0
17
Conventional tumor markers may serve as adjuncts in non-small cell lung cancer (NSCLC) management. In a new study, researchers Scott Strum, Mark Vincent, Meghan Gipson, Eric McArthur, and Daniel Breadner from the Schulich ...
Jun 21, 2024
0
70
Fibroblast activation protein (FAP)-targeted radioligand therapy is safe and effective for treating patients with progressive metastatic tumors, specifically advanced sarcomas, according to research presented at the 2024 ...
Jun 10, 2024
0
37
Clinical trials for cancer drugs have three stages, Phase I–III, before marketing, each with different evaluation items. However, there is no consensus on the appropriateness of evaluation criteria for early-stage clinical ...
Apr 8, 2024
0
23
The Response Evaluation Criteria In Solid Tumors (RECIST), used in many clinical trials to evaluate changes in tumor burden over time, classify objective tumor response into one of four categories (complete or partial response, ...
Jun 3, 2023
0
54
Researchers from the University of Colorado Cancer Center on the Anschutz Medical Campus have created a new way of measuring cancer lesions response to treatment that could better inform the development of new cancer drugs.
Sep 30, 2022
0
38
